Verastem Oncology

(NASDAQ: VSTM)
Healthcare  |  Biotechnology
0.90 -0.0421 -4.45%
Stock Price | Nov. 15, 2019, 4 p.m.
0 Followers
Bid: 0.0
Ask: 0.0
Prev. Close: 0.9454
52 Week Low: 0.8802
52 Week High: 5.71
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Read more Read less

Recently Viewed Tickers

Premium Stock Watchlist 11/04/2015

4 years ago

Premium Stock Watchlist 11/02/2015

4 years ago

Premium Stock Watchlist 10/15/2015

4 years ago

Premium Stock Watchlist Video 08/13/2015

4 years ago

Premium Stock Watchlist 08/12/2015

4 years ago

Free Top 10 Stocks Corporate Insiders Are Buying Heavily This Week

4 years ago

Free Top 10 Stocks Corporate Insiders Are Buying Heavily This Week

4 years ago

Free Stocks On My Radar This Week - 1/12/15

4 years ago